Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the S...
September 26 2018 - 7:05AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty
pharmaceutical company that develops and markets unique and
effective solutions for the treatment of dermatological conditions
and advanced tissue care, today announced it has licensed its
antimicrobial hypochlorous acid eye solution for management of
blepharitis to Brill Pharma, S.L. in the Spanish and Portuguese
markets.
The formulation, marketed in the United States as Acuicyn™
Eyelid and Eyelash Hygiene solution, is a safe and efficacious
method to keep areas around the eye and eyelids/eyelashes
clean. Sonoma’s performance-stabilized 100% hypochlorous acid
(HOCl), which is at the heart of Acuicyn, can be used safely around
eyes, ears, nose and mouth without concerns about toxicity or
stinging.
The Spanish/Portuguese formulation, to be branded as Ocudox™,
will be marketed as a pre-surgical antimicrobial for use in eye
surgery, intraoculus injections and any eye manipulation that
requires sterile conditions.
“We believe Spanish and Portuguese eye care professionals will
find much to like about Ocudox with its rapid triple mode of action
for treatment of eye conditions: Infection control,
inflammation control and regeneration of healthy tissue around the
eyes,” said Dr. Jordi Martínez Rotllan, director at Brill Pharma,
S.L. “Yet, at the same time, the formulation is highly safe
without side effects or any change to the patient’s DNA. We believe
the Spanish and Portuguese eye care professionals will be highly
receptive to the superiority of the Sonoma performance-stabilized
HOCl formulation.”
Ocudox is expected to become available in Spain and Portugal
beginning early 2019. For more information or to order, visit
http://www.brillpharma.com/en/.
“We are pleased to introduce this cutting-edge advance in eye
care into Spain and Portugal,” said Jim Schutz, CEO of Sonoma
Pharmaceuticals. “Our proprietary and patented HOCl is truly
the next-generation formulation in terms of superior antimicrobial
impact, shelf stability and safety. HOCl clinical trials
confirm immediate and meaningful relief from conditions associated
with eye afflictions including blepharitis, meibomian gland
dysfunction, demodex and dry eye.”
About Brill Pharma, S.L. Brill Pharma
Laboratories is a pharmaceutical company based in Barcelona,
Spain. The company researches, develops, produces, licenses
and commercializes ophthalmology products. Brill Pharma is the
fastest growing pharmaceutical company in Spain and the first in
the market among the nationals. Brill Pharma Laboratories
consists of a team of 100 professionals and offers the largest
sales force targeting ophthalmologists in Spain. More
information can be found at www.brillpharma.com.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s products, sold
throughout the United States and internationally, have improved
outcomes for more than five million patients globally by
reducing infections, itch, pain, scarring and harmful
inflammatory responses. The company's headquarters are in Petaluma,
California, with manufacturing operations in the United States
and Latin America. European marketing and sales are
headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “licensed,”
“marketed,” and “branded,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals® and Acuicyn™ are registered trademarks
of Sonoma Pharmaceuticals, Inc. All other trademarks and
service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.Bob MillerCFO(925)
787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Sep 2023 to Sep 2024